论文部分内容阅读
目的 :探讨细胞凋亡相关基因bcl 2、p5 3在前列腺癌中的表达及意义。 方法 :应用免疫组织化学ABC法 ,检测 3 6例前列腺癌 (Pca) ,2 0例前列腺增生 (BPH )组织和 11例正常前列腺组织 (NP)中bcl 2、p5 3蛋白表达。结果 :①Pca和BPH组bcl 2蛋白阳性表达率明显高于NP组 (P <0 .0 5 ) ,而Pca组与BPH组阳性率无显著性差异。Pca组 p5 3蛋白阳性表达率明显高于BPH组和NP组 (P <0 .0 5 ) ,而BPH组与NP组阳性率无显著性差异 (P >0 .0 5 )。②在Pca组中bcl 2蛋白阳性 10例 ,其中Ⅰ、Ⅱ级肿瘤组阳性 4例 ,Ⅲ、Ⅳ级肿瘤组 6例 (P <0 .0 5 ) ;p5 3蛋白阳性 12例 ,其中Ⅰ、Ⅱ级肿瘤组阳性 5例 ,Ⅲ、Ⅳ级肿瘤组 7例 (P <0 .0 5 )。显示bcl 2、p5 3蛋白表达随着病理分级的增高而增高。③p5 3蛋白表达阳性率≤ 5年生存组明显高于>5年生存组 ,呈负相关 (P <0 .0 5 )。bcl 2蛋白表达与生存期无关 (P >0 .0 5 )。结论 :p5 3、bcl 2蛋白的异常表达与前列腺癌的发生发展、病理分级及预后有关。
Objective: To investigate the expression and significance of apoptosis-related genes bcl 2 and p 5 3 in prostate cancer. Methods: Immunohistochemical ABC method was used to detect the expression of bcl 2 and p 5 3 proteins in 36 cases of prostate cancer (Pca), 20 cases of benign prostatic hyperplasia (BPH) and 11 cases of normal prostatic tissue (NP). Results: (1) The positive rates of bcl-2 protein in both Pca and BPH groups were significantly higher than those in NP group (P <0.05), but there was no significant difference between Pca group and BPH group. The positive rate of p5 3 protein in Pca group was significantly higher than that in BPH group and NP group (P <0.05), but there was no significant difference between BPH group and NP group (P> 0.05). ② In the Pca group, 10 cases were positive for bcl 2 protein, of which 4 cases were positive for grade Ⅰ and Ⅱ tumors, 6 cases were grade Ⅲ and Ⅳ tumors (P <0.05), and 12 cases were positive for p5 3 protein. Among them, Grade Ⅱ tumors were positive in 5 cases, grade Ⅲ, Ⅳ tumors in 7 cases (P <0. 05). The results showed that the expression of bcl 2 and p5 3 protein increased with the increase of pathological grade. ③ The positive rate of p5 3 protein expression in ≤5-year survival group was significantly higher than that in> 5-year survival group (P <0.05). The expression of bcl 2 protein had no relation with survival (P> 0.05). Conclusion: The abnormal expression of p53 and bcl2 proteins is related to the development, pathological grade and prognosis of prostate cancer.